Protein Biochips: Parallelized Screening for High-Output Biology

SAN FRANCISCO, July 28 2004 /PR Newswire/ —. The protein biochip industry is shedding hype and demonstrating real value. The grandiose visions of technologies to study the entire human proteome are giving way to pragmatic divide-and-conquer approaches. This transition is driving the projected growth in the market from $122 million in 2002 to more than $500 million in 2008, according to a new report, Protein Biochips: Parallelized Screening for High-Output Biology, from BioPerspectives in San Francisco, California, Bachmann Consulting in Nesoddtangen, Norway, and the NMI Natural and Medical Sciences Institute at the University of Tübingen in Germany.

The report, written by an international team of experts, has unparalleled analysis and coverage of the protein biochip market, including both planar and bead arrays. The report features a detailed discussion of the key drivers that are likely to cause major shifts in the emerging market, ranging from the content problem to the looming bottleneck in target validation to the current bottleneck in lead optimization to the enthusiasm over protein biomarkers. The comprehensive report features detailed evaluations of the technologies and business strategies of 61 companies, plus summaries of 9 companies currently using bead-based assays for diagnostics.

In addition, the report features a detailed, hierarchical market model. At the highest level, the market is divided into three application areas: (1) drug target and biomarker identification and validation, (2) drug development, and (3) clinical trials and diagnostics. At the next level, the market is divided by biochip dimension: 2-dimensional planar arrays and 3-dimensional bead arrays. The next level is the type of biochip: capture and interaction. At the lowest level: hardware and biochips.

Furthermore, to enable readers to take full advantage of the expertise of the authors, the report comes with one free hour of consulting. Steven Bodovitz and Jutta Bachmann will be available for conference calls to discuss market drivers, company evaluations, and financial projections.

To request more information or to order a copy of the report, please (1) visit www.bioperspectives.com or www.jbachmann-consulting.com or (2) call BioPerspectives in the United States at 415-336-2700 or Bachmann Consulting in Norway at +47-6691-2809.

SOURCE: BioPerspectives

CONTACT: Steven Bodovitz, Principal, BioPerspectives, 415-336-2700 or bodovitzs@bioperspectives.com